SAREUM HOLDINGS PLC Logo

SAREUM HOLDINGS PLC

Clinical-stage developer of kinase inhibitors for autoimmune disease & cancer.

SAR | IL

Overview

Corporate Details

ISIN(s):
GB00BMC3RJ87
LEI:
213800PKERN2DY8FFM72
Country:
United Kingdom
Address:
UNIT 2A, CB22 3FX CAMBRIDGE
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Sareum Holdings PLC is a clinical-stage drug discovery and development company specializing in small molecule therapeutics. The company develops next-generation kinase inhibitors to treat autoimmune diseases and cancer. Its primary focus is on the TYK/JAK kinase cell signalling family, advancing dual inhibitors of TYK2 and JAK1, which it believes offer superior efficacy compared to single-kinase agents. The company's lead autoimmune candidate, SDC-1801, has successfully completed a Phase 1 clinical trial. Sareum's pipeline also includes a Chk1 kinase inhibitor program for oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-10 08:00
Legal Proceedings Report
Update on toxicology study for SDC-1801
English 13.2 KB
2025-10-07 08:00
Report Publication Announcement
Notice of Results and Investor Presentation
English 12.2 KB
2025-09-26 16:12
Share Issue/Capital Change
Exercise of Warrants
English 10.8 KB
2025-09-18 13:59
Share Issue/Capital Change
Exercise of Warrants
English 10.9 KB
2025-08-26 08:00
Share Issue/Capital Change
Exercise of Warrants
English 10.5 KB
2025-08-20 11:01
Share Issue/Capital Change
Exercise of Warrants
English 10.5 KB
2025-08-12 08:00
Regulatory News Service
Sareum Collaboration with Receptor.AI
English 15.3 KB
2025-07-09 08:00
Share Issue/Capital Change
Exercise of Warrants
English 10.7 KB
2025-05-29 08:00
Regulatory News Service
Initiation of Toxicology Studies for SDC-1801
English 11.4 KB
2025-03-27 08:00
Director's Dealing
Director’s Dealing
English 27.8 KB
2025-03-25 08:00
Interim Report
Sareum Half-Year Report
English 133.9 KB
2025-03-13 08:15
Share Issue/Capital Change
Institutional Equity Fundraise
English 14.4 KB
2025-03-13 08:08
Regulatory News Service
Sareum Acquires Licence for SRA737
English 12.8 KB
2024-12-31 08:00
Legal Proceedings Report
Update on SRA737
English 13.5 KB
2024-12-19 17:07
Post-Annual General Meeting Information
Results of AGM
English 33.8 KB

Automate Your Workflow. Get a real-time feed of all SAREUM HOLDINGS PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for SAREUM HOLDINGS PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Medivir Logo
Clinical-stage pharma firm developing tumor-directed therapies for high-need cancer patients.
Sweden MVIR
Sweden MBOLIC
Milton Essex Spolka Akcyjna Logo
Develops AI-powered, non-invasive systems for allergy diagnostics & personalized medicine.
Poland MTN
Molecular Partners AG Logo
Pioneering DARPin protein drugs for complex diseases in oncology and virology.
Switzerland MOLN
MorphoSys AG Logo
Biopharma company creating antibody therapies for oncology, with a focus on blood cancers.
Germany MOR
Mycodern Spolka Akcyjna Logo Poland MCD
N4 PHARMA PLC Logo
Developing a nanoparticle delivery system for advanced gene and vaccine therapies.
United Kingdom N4P
NextGen Biomed Ltd. Logo
R&D of biotech medical devices for diabetes care and topical skin treatments.
Israel NXGN
Nicox S.A. Logo
Developing innovative ophthalmology drugs for glaucoma and ocular hypertension.
France COX
ONCIMMUNE HOLDINGS PLC Logo
Antibody biomarker discovery platform for pharma and biotech partners in oncology and autoimmune disease.
United Kingdom ONC

Talk to a Data Expert

Have a question? We'll get back to you promptly.